US Edition
Published • loading... • Updated
SCG announces presentation of clinical results of SCG142 in patients with HPV-related carcinoma at ESMO 2025
- SCG Cell Therapy Pte Ltd announced the presentation of first-in-human clinical data for SCG142 in patients with HPV-associated carcinomas at the ESMO Congress 2025 in Berlin, Germany, on October 18, 2025.
- The trial showed tumor shrinkage in all seven treated patients, leading to a 100% disease control rate.
- Prof. Dr. Yang Li stated that these findings support further evaluation in larger patient cohorts for patients with HPV-associated cancers.
- Dr. Susanne Wilde expressed satisfaction that the preclinical profile of SCG142 has translated into clinical activity.
Insights by Ground AI
42 Articles
42 Articles
Rutland Herald+40 Reposted by 40 other sources
SCG announces presentation of clinical results of SCG142 in patients with HPV-related carcinoma at ESMO 2025
SINGAPORE, Oct. 18, 2025 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing next-generation immunotherapies for infectious diseases and their associated cancers, announced the presentation of first-in-human clinical data for SCG142 in an investigator-initiated Phase I…
Coverage Details
Total News Sources42
Leaning Left9Leaning Right5Center9Last UpdatedBias Distribution39% Left, 39% Center
Bias Distribution
- 39% of the sources lean Left, 39% of the sources are Center
39% Center
L 39%
C 39%
R 22%
Factuality
To view factuality data please Upgrade to Premium
